Klinische Wochenschrift

, Volume 66, Issue 2, pp 43–47

Cyclosporin-associated nephropathy in patients with autoimmune diseases

Authors

  • M. J. Mihatsch
    • Institut für PathologieUniversität Basel
  • J. F. Bach
    • Service d'Immunologie CliniqueHôpital Necker
  • H. M. Coovadia
    • Department of PaediatricsUniversity of Natal and King Edward VIII Hospital
  • Ø. Førre
    • Oslo AnitetsforeningsRheumatism Hospital
  • H. M. Moutsopoulos
    • Department of MedicineUniversity of Ioannina
  • A. A. Drosos
    • Department of MedicineUniversity of Ioannina
  • K. C. Siamopoulos
    • Department of MedicineUniversity of Ioannina
  • L. H. Noël
    • Service d'Immunologie CliniqueHôpital Necker
  • R. Ramsaroop
    • Department of PaediatricsUniversity of Natal and King Edward VIII Hospital
  • R. Hällgren
    • Dept. Int. Medicine, Section of RheumatologyUniversity Hospital
  • K. Svenson
    • Dept. Int. Medicine, Section of RheumatologyUniversity Hospital
  • S. O. Bohman
    • Department of Pathology, Karolinska InstituteHuddinge Hospital
Originalien

DOI: 10.1007/BF01713009

Cite this article as:
Mihatsch, M.J., Bach, J.F., Coovadia, H.M. et al. Klin Wochenschr (1988) 66: 43. doi:10.1007/BF01713009

Summary

Renal biopsy specimens were evaluated from patients with different autoimmune diseases treated with cyclosporin (CyA). Ten biopsies were done before CyA, 10 biopsies after low-dose (<7.5 mg/kg/day, initial dose or mean daily dose within the first month, respectively), and 9 after high-dose (>7.5 mg/kg/day) treatment. Definite chronic CyA nephrotoxicity (cyclosporin-associated arteriolopathy and/or interstitial fibrosis striped form with tubular atrophy) was only present in the initial high-dose group. In this group a significant serum creatinine increase was noted and 8 of the 9 patients were hypertensive. No significant correlation was found between the severity of morphologic lesions and the mean daily dose during total treatment, cumulative dose, and duration of therapy. The morphologic changes in the low-dose group did not differ from the control biopsy specimens before CyA treatment. Based on these results, it can be concluded that major nephrotoxicity can be avoided by initial low CyA doses.

Key words

CyclosporinNephropathySide effectsAutoimmune disease

Abbreviations

CyA

Cyclosporin A

NSAID

Nonsteroidal antiinflammatory drugs

SLE

Systemic lupus erythematosus

Copyright information

© Springer-Verlag 1988